Institutional Movements - Long-term funds are continuously increasing their investments in the innovative drug sector amid recent market adjustments, indicating a long-term value in this sector, although a focus on quality companies is necessary due to previous strong price increases [1] Long-term Funds Entering via ETFs - Several newly launched innovative drug-themed ETFs have seen significant purchases from long-term funds this year, with Barclays Bank being a major holder of multiple ETFs, holding 20 million yuan in one and 85 million yuan in another [2] - Corporate pension plans have also heavily invested in innovative drug ETFs, with several plans holding over 40 million yuan each [2] - As of July 3, the Huatai-PineBridge Hang Seng Innovative Drug ETF has increased by over 60% since its launch, while the ICBC Credit Suisse National Index Hong Kong Innovative Drug ETF has risen nearly 30% [2] Fund Flows - The innovative drug-themed ETFs have attracted substantial net subscriptions, totaling nearly 9 billion yuan since June, with specific ETFs like the Huatai-PineBridge and GF Hong Kong Innovative Drug ETFs seeing net subscriptions of 4.44 billion yuan and 2.305 billion yuan, respectively [3] New Fund Launches - Public funds are increasing their focus on innovative drug-themed funds, with several new funds currently being issued, including the Xinyuan CSI Hong Kong Innovative Drug Index Fund and others set to launch soon [4] Long-term Outlook for the Innovative Drug Industry - The innovative drug sector in China is expected to continue its long-term positive trend, with significant overseas collaborations and clinical advancements being recognized by multinational pharmaceutical companies [5] - The recent rise in the innovative drug sector is attributed to a decade of accumulated competitive advantages rather than short-term market fluctuations, suggesting ongoing investment opportunities in quality innovative drug companies [5] - The industry is likely to experience linear development, while market performance may be more volatile, necessitating a focus on fundamental research and selective investment strategies [5]

一 上周市场回顾 一、上周市场回顾 上周 A 股市场主要宽基指数走势出现分化，创业板指、上证综指、沪深 300 指数收益靠前，收益分别为 0.22% 、 -0.25% 、 -0.25% ，科创 50 、中证 1000 、中小板指指数收益靠后，收益分别为 -1.89% 、 -0.76% 、 -0.65% 。 从成交额来看，上周主要宽基指数成交额均有所上升。行业方面，上周有色 金 属 、 石 油 石 化 、 医 药 收 益 靠 前 ， 收 益 分 别 为 3.95% 、 3.31% 、 1.54% ，食品饮料、计算机、建材收益靠后，收益分别为 -4.42% 、 -2.25% 、 -2.16% 。 截至上周五，央行逆回购净回笼资金 727 亿元，逆回购到期 9309 亿元， 净公开市场投放 8582 亿元。不同期限的国债利率均有所下行，利差缩窄 0.07BP 。 上周共上报 24 只基金，较上上周申报数量有所减少。申报的产品包括 2 只 FOF ，嘉实恒生消费 ETF 、鹏华国证港股通创新药 ETF 、交银施罗德 恒生港股通创新药精选指数基金、天弘国证港股通科技指数基金、泰信中证 全指自由现金流指数基金、大成创业板 ...